(Q33360152)

English

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer

scientific article

Statements

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit